3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Andersen Group Inc. appointed Daniel DePaoli and Peter Coscia, both longtime senior executives, to its Board of Directors effective October 13, 2026. The Board size increases from 8 to 10 directors, and the company says the appointments add operational expertise as it pursues global growth.
Daniel DePaoli and Peter Coscia appointed to the Board, effective October 13, 2026
Board size increased from 8 directors to 10
DePaoli has held senior leadership roles at Andersen since 2002; Coscia has held leadership roles there since 2002
Filing does not disclose financial results or compensation terms for the new directors
Comtech said CFO Michael Bondi will leave after he files the first-quarter fiscal 2027 Form 10-Q, and Richard Nyren, now Executive Vice President, Finance, will become CFO at that point. The company tied the changes to the anticipated closing of the sale of most of its Satellite and Space Communications business to an affiliate of Gilat Satellite Networks, and it also named Amy Rothstein-Hovey as General Counsel. The filing says Bondi's departure is amicable and not the result of any disagreement on accounting, financial reporting or controls.
Bondi remains CFO through the filing of the first-quarter fiscal 2027 Form 10-Q, currently anticipated by December 10, 2026
Nyren, age 56, has an annualized base salary of $425,000, a 75% target bonus and a $100,000 sign-on bonus
Bondi receives a lump sum severance of 2.0 times his base salary plus target bonus, plus $500,000 and $300,000 cash payments in place of certain equity awards
Rothstein-Hovey joined as General Counsel on October 1, 2026, succeeding Don Walther, who remains through the S&S closing
On October 8, 2026, KB Home's compensation committee approved performance-based restricted stock unit awards to CEO Robert V. McGibney, Jeffrey T. Mezger and Brian J. Woram. The awards vest based on three-year cumulative earnings per share, average return on invested capital and relative revenue growth over December 1, 2026 to November 30, 2029, and this routine compensation disclosure does not change reported results.
Enliven Therapeutics appointed Kristine Ball as a Class II director and Audit Committee member, effective October 14, 2026, expanding the board from seven to eight directors. The company says the appointment comes as it prepares to start the pivotal Phase 3 ENABLE-2 trial of relcobatinib before year-end 2026, a routine governance change with no financial results disclosed.
Kristine Ball appointed Class II director, term expiring at the 2028 annual meeting, and Audit Committee member, effective October 14, 2026
Ball receives $45,000 per year as an outside director and $10,000 per year for Audit Committee service
Initial stock option grant with a grant date fair value of approximately $650,000, vesting monthly over 36 months
Company plans to initiate the Phase 3 ENABLE-2 trial of relcobatinib before year-end 2026
Mattel amended the September 29, 2026 offer letter with Roger Lynch, its Chief Executive Officer, setting his start date as October 12, 2026 and moving the timing of his initial equity awards to that date. The amendment also raises his change-in-control severance multiplier to 2.99 times from two times for terminations on or before December 31, 2028, and adds an excise tax make-whole payment for changes of control on or before that date, which shareholders may view as added cost tied to the CEO's pay package.
Start date set as October 12, 2026; make-whole, inducement and 2026 annual long-term awards now granted on that date rather than the last trading day of the month
Awards total 461,538 make-whole RSUs, 461,538 inducement PSUs and 461,538 annual PSUs at target plus 307,692 annual RSUs
Change-in-control cash severance multiplier raised to 2.99 times from two times for qualifying terminations through December 31, 2028
Excise tax make-whole provision applies to a change of control on or before December 31, 2028; the filing says the amendment followed recent external developments
Lisata Therapeutics' board increased its size from seven to eight members and appointed Jeffrey Farrow, currently CFO and Chief Strategy Officer of Tarsus Pharmaceuticals, to fill the new seat effective October 13, 2026. Mr. Farrow also joined the Audit Committee, and the board determined he is independent under Nasdaq listing rules.
Appointed effective October 13, 2026 as a Class III director, with an initial term expiring at the 2028 annual meeting
Joins the Audit Committee; the board determined he is independent under Nasdaq Capital Market listing rules
Has been CFO and Chief Strategy Officer of Tarsus Pharmaceuticals since April 2023 and previously served as CFO of Global Blood Therapeutics until its acquisition by Pfizer in December 2022
Jackson Financial's board elected Donald C. Templin as a new independent director on October 12, 2026, filling the vacancy left by Gregory Durant's resignation earlier this year. He also joined the Audit and Compensation Committees, and the filing says he qualifies as an audit committee financial expert, which matters to shareholders because it adds audit oversight experience to the board.
Board elected Templin on October 12, 2026, for a term ending at the 2027 Annual Meeting of Shareholders
Templin fills the vacancy from Gregory Durant's resignation and joins the Audit and Compensation Committees
Non-employee director pay is an annual cash retainer of $125,000 and an annual equity grant valued at $185,000
Templin is former Executive Vice President and Chief Financial Officer of Voya Financial and previously a certified public accountant at PricewaterhouseCoopers LLP
Green Dot Corporation disclosed that General Counsel Amy Pugh notified the company on October 8, 2026, that she will resign to pursue another professional opportunity. Her resignation takes effect November 2, 2026. The filing does not name a successor or describe any compensation arrangements.
Amy Pugh notified Green Dot of her decision to resign as General Counsel on October 8, 2026.
Her resignation is effective November 2, 2026.
She is leaving to pursue another professional opportunity; the filing does not name a successor.
Yext's board on October 11, 2026 approved a nonstatutory stock option for CEO Michael Walrath covering 11,000,000 shares at a $7.00 exercise price, a premium to the $6.93 close on October 9, 2026. The option vests only if the stock hits one of 14 escalating price targets over up to ten years, and it requires stockholder approval within twelve months. The grant is significant because it aligns the CEO's potential pay with large share price gains, but its value depends entirely on those gains being achieved.
Option covers 11,000,000 shares at $7.00 per share, with a ten-year term
Vesting is tied to 14 tranches with target prices from $21.00 to $88.08 per share
Option is subject to stockholder approval within twelve months and is granted outside the 2016 Equity Incentive Plan
Exhibit 10.1, the Stand-Alone Stock Option Agreement dated October 11, 2026, is filed with the report
Sprouts Farmers Market said its Chief Technology Officer, James Bahrenburg, stepped down on October 12, 2026, and that the departure was not due to any disagreement with the company. He will serve as an advisor through March 31, 2027 to support an orderly transition, and remains eligible for severance under the company's executive severance plan.
James Bahrenburg stepped down as Chief Technology Officer on October 12, 2026
Departure was not the result of any disagreement with the company on operations, policies or practices
Bahrenburg will advise the company through March 31, 2027, keeping existing equity awards vesting and remaining eligible for cash bonus plan amounts
He is also eligible for severance under the Amended and Restated Executive Severance and Change in Control Plan
Longeveron Inc. disclosed that Chief Medical Officer Dr. Nataliya Agafonova informed management on October 7, 2026, of her decision to step down, effective October 14, 2026. The filing does not state a successor or the reason for her departure.
Dr. Nataliya Agafonova informed management on October 7, 2026, of her decision to step down as Chief Medical Officer.
The departure takes effect October 14, 2026.
The filing does not name a replacement or give a reason for the departure.
PC Connection, Inc. (CNXN) said Matthew Zafirovski joined the company as President and Chief Operating Officer effective October 12, 2026, reporting to CEO Timothy McGrath. McGrath ceased serving as President but remains Chief Executive Officer. The filing describes a new executive hire with a $700,000 base salary and a 25,000 restricted stock unit grant.
Matthew Zafirovski, 41, was CEO of Tusker from 2022 to 2026 and COO of Tusker from 2020 to 2022
Base salary of $700,000; bonus eligibility at a basic rate of 100% of base salary under the Executive Bonus Plan
Grant of 25,000 restricted stock units vesting 25% per year, starting on the first anniversary of the grant date
Severance equal to base salary for the shorter of six months or until he secures other employment, if terminated without cause, death, or disability
Kulicke and Soffa's compensation committee approved an amended and restated Incentive Compensation Plan on October 13, 2026, effective for fiscal 2027. The plan swaps Net Income and Operating Margin for Operating Profit and Gross Margin as corporate performance measures, and adds an individual goal component for Executive Leadership Team awards. For shareholders, this changes how management bonuses are tied to financial results.
Corporate performance measures changed from Net Income and Operating Margin (50% each) to Operating Profit and Gross Margin (50% each)
For fiscal 2027, Executive Leadership Team awards will be 85% based on corporate financial performance and 15% on individual goals
Business unit scorecards may be tailored by growth phase and strategic priorities, within existing governance
Plan approved October 13, 2026; filed in Form 8-K dated October 14, 2026
TOP Financial Group Limited said it has established its global headquarters in Houston, Texas, and restructured its Board of Directors and senior leadership. The filing says the executive team's relocation to the United States is being implemented in phases, and the Board has grown from five to seven directors with new leadership appointments. The filing reports no financial results, so the changes are governance and leadership moves rather than a change in reported performance.
Board size increased from five to seven directors, under the Nominating and Corporate Governance Committee's guidance.
Jennifer Hoi Ling Tam appointed Co-Chief Executive Officer and Executive Director; Dean Huge added as Independent Director; Yuli Yan added as Executive Director.
Principal executive office established at 4201 Main Street, Suite 200, Houston, Texas 77002, following a September 4, 2026 announcement.
North American region holds 85.7% of board representation; the UK citizen accounts for the remaining 14.3%.
Akebia Therapeutics said its Senior Vice President and Chief Commercial Officer, Nicholas Grund, will resign effective November 6, 2026, for personal reasons. Under a consulting agreement, he will advise the company until April 30, 2027, and be paid an hourly rate.
Nicholas Grund notified the company of his resignation on October 7, 2026.
Resignation takes effect November 6, 2026.
Consulting Period runs until April 30, 2027; either side can end it early with notice (10 days for the company, 30 days for Mr. Grund).
The filing does not state a replacement for the chief commercial officer role.
Compass, Inc. said Lead Independent Director Charles E. Phillips resigned from its board effective October 9, 2026, to devote more time to commitments outside real estate, and that the resignation was not due to any disagreement with the company. The board named Frank Martell Lead Independent Director and Steven Sordello chair of the Nominating and Corporate Governance Committee, and appointed technology executive Sissie L. Hsiao to fill the vacancy, adding her to the Compensation Committee. The filing contains no financial results, so the changes are governance updates rather than a direct financial event.
Charles E. Phillips resigned from the board effective October 9, 2026, and gave up his Lead Independent Director and committee roles.
Frank Martell, Audit Committee chair, became Lead Independent Director effective October 9, 2026.
Sissie L. Hsiao, a former Google executive, joins the board effective October 14, 2026, as a Class II director with a term expiring in 2029 and sits on the Compensation Committee.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.